Yasufumi Matsumura1,2, Gisele Peirano3,4, Rebekah Devinney1, Patricia A Bradford5, Mary R Motyl6, Mark D Adams7, Liang Chen8, Barry Kreiswirth8, Johann D D Pitout1,3,4,9. 1. Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada. 2. Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. 3. Departments of Pathology & Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada. 4. Division of Microbiology, Calgary Laboratory Services, Calgary, Alberta, Canada. 5. AstraZeneca Pharmaceuticals LP, Waltham, MA, USA. 6. Merck & Co., Inc, Rahway, NJ, USA. 7. Department of Medical Microbiology, J. Craig Venter Institute, La Jolla, CA, USA. 8. Public Research Institute TB Center, New Jersey Medical School, Rutgers University, Newark, NJ, USA. 9. Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa.
Abstract
Background: International data on the molecular epidemiology of Enterobacteriaceae with VIM carbapenemases are limited. Methods: We performed short read (Illumina) WGS on a global collection of 89 VIM-producing clinical Enterobacteriaceae (2008-14). Results: VIM-producing (11 varieties within 21 different integrons) isolates were mostly obtained from Europe. Certain integrons with bla VIM were specific to a country in different species and clonal complexes (CCs) (In 87 , In 624 , In 916 and In 1323 ), while others had spread globally among various Enterobacteriaceae species (In 110 and In 1209 ). Klebsiella pneumoniae was the most common species ( n = 45); CC147 from Greece was the most prevalent clone and contained In 590 -like integrons with four different bla VIM s. Enterobacter cloacae complex was the second most common species and mainly consisted of Enterobacter hormaechei ( Enterobacter xiangfangensis , subsp. steigerwaltii and Hoffmann cluster III). CC200 (from Croatia and Turkey), CC114 (Croatia, Greece, Italy and the USA) and CC78 (from Greece, Italy and Spain) containing bla VIM-1 were the most common clones among the E. cloacae complex. Conclusions: This study highlights the importance of surveillance programmes using the latest molecular techniques in providing insight into the characteristics and global distribution of Enterobacteriaceae with bla VIM s.
Background: International data on the molecular epidemiology of Enterobacteriaceae with VIM carbapenemases are limited. Methods: We performed short read (Illumina) WGS on a global collection of 89 VIM-producing clinical Enterobacteriaceae (2008-14). Results: VIM-producing (11 varieties within 21 different integrons) isolates were mostly obtained from Europe. Certain integrons with bla VIM were specific to a country in different species and clonal complexes (CCs) (In 87 , In 624 , In 916 and In 1323 ), while others had spread globally among various Enterobacteriaceae species (In 110 and In 1209 ). Klebsiella pneumoniae was the most common species ( n = 45); CC147 from Greece was the most prevalent clone and contained In 590 -like integrons with four different bla VIM s. Enterobacter cloacae complex was the second most common species and mainly consisted of Enterobacter hormaechei ( Enterobacter xiangfangensis , subsp. steigerwaltii and Hoffmann cluster III). CC200 (from Croatia and Turkey), CC114 (Croatia, Greece, Italy and the USA) and CC78 (from Greece, Italy and Spain) containing bla VIM-1 were the most common clones among the E. cloacae complex. Conclusions: This study highlights the importance of surveillance programmes using the latest molecular techniques in providing insight into the characteristics and global distribution of Enterobacteriaceae with bla VIM s.
Authors: S Melegh; K Kovács; T Gám; A Nyul; B Patkó; A Tóth; I Damjanova; G Mestyán Journal: Clin Microbiol Infect Date: 2013-06-28 Impact factor: 8.067
Authors: C C Papagiannitsis; R Izdebski; A Baraniak; J Fiett; M Herda; J Hrabák; L P G Derde; M J M Bonten; Y Carmeli; H Goossens; W Hryniewicz; C Brun-Buisson; M Gniadkowski Journal: J Antimicrob Chemother Date: 2015-03-10 Impact factor: 5.790
Authors: Christine Lascols; Gisele Peirano; Meredith Hackel; Kevin B Laupland; Johann D D Pitout Journal: Antimicrob Agents Chemother Date: 2012-10-15 Impact factor: 5.191
Authors: R Izdebski; A Baraniak; M Herda; J Fiett; M J M Bonten; Y Carmeli; H Goossens; W Hryniewicz; C Brun-Buisson; M Gniadkowski Journal: J Antimicrob Chemother Date: 2014-09-12 Impact factor: 5.790
Authors: Krystyna M Kazmierczak; Sharon Rabine; Meredith Hackel; Robert E McLaughlin; Douglas J Biedenbach; Samuel K Bouchillon; Daniel F Sahm; Patricia A Bradford Journal: Antimicrob Agents Chemother Date: 2015-12-07 Impact factor: 5.191
Authors: David M P De Oliveira; Brian M Forde; Timothy J Kidd; Patrick N A Harris; Mark A Schembri; Scott A Beatson; David L Paterson; Mark J Walker Journal: Clin Microbiol Rev Date: 2020-05-13 Impact factor: 26.132
Authors: Tse H Koh; Nurdyana Binte Abdul Rahman; Jeanette W P Teo; My-Van La; Balamurugan Periaswamy; Swaine L Chen Journal: Genome Announc Date: 2018-01-04